Aurobindo Pharma looks to sell cancer drugs in the US by year end

Industry News /

Hyderabad-based pharma major says US FDA approval likely to come after upcoming audit Hyderabad-based Aurobindo Pharma Limited is hoping to receive three-four product approvals in the oncology space from the US Food and Drug Administration (US FDA) before March 2018. The company’s optimistic prediction about a possible good start in this high-margin product business comes […]

Aurobindo Pharma looks to sell cancer drugs in the US by year end Read More »

Aurobindo Receives FDA Approval for Glipizide Extended-Release Tablets, 2.5 mg, 5 mg and 10 mg

Product News /

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Glipizide Extended-Release Tablets, 2.5 mg, 5 mg and 10 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Glipizide Extended-Release Tablets, 2.5 mg, 5 mg and 10 mg to be bioequivalent and, therefore, therapeutically equivalent

Aurobindo Receives FDA Approval for Glipizide Extended-Release Tablets, 2.5 mg, 5 mg and 10 mg Read More »

Aurobindo Receives FDA Approval for Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg

Product News /

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/20 mg, 5

Aurobindo Receives FDA Approval for Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg Read More »

Aurobindo Receives FDA Approval for Olmesartan Medoxomil and Hydrochlorothiazide Tablets

Product News /

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and

Aurobindo Receives FDA Approval for Olmesartan Medoxomil and Hydrochlorothiazide Tablets Read More »

Aurobindo Receives FDA Approval for Olmesartan Medoxomil Tabs, 5, 20, & 40 mg

Product News /

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Olmesartan Medoxomil Tablets, 5 mg, 20 mg, and 40 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Olmesartan Medoxomil Tablets, 5 mg, 20 mg, and 40 mg to be bioequivalent and, therefore, therapeutically equivalent

Aurobindo Receives FDA Approval for Olmesartan Medoxomil Tabs, 5, 20, & 40 mg Read More »

Aurobindo USA welcomes Senior VP of Commercial Operations

Industry News /

Aurobindo USA is proud to announce and welcome Paul Krauthauser as the company’s Senior Vice President of Commercial Operations reporting to Bob Cunard, Chief Executive Officer. Paul will be responsible for the retail generic business. He has more than 20 years of experience in US Pharmaceutical Sales including but not limited to demand planning, contracting

Aurobindo USA welcomes Senior VP of Commercial Operations Read More »

President Donald Trump’s nomination of Dr. Scott Gottlieb to lead the Food and Drug Administration signals he is serious about increasing access to safe, effective and…

Industry News /

(March 11, 2017) WASHINGTON, DC  – “President Donald Trump’s nomination of Dr. Scott Gottlieb to lead the Food and Drug Administration signals he is serious about increasing access to safe, effective and affordable medicines for Americans while taking a market based, competitive approach towards lowering drug costs. Dr. Gottlieb is one of the most formidable

President Donald Trump’s nomination of Dr. Scott Gottlieb to lead the Food and Drug Administration signals he is serious about increasing access to safe, effective and… Read More »

Aurobindo Pharma USA is in the midst of a major expansion to its U.S. footprint.

Industry News /

The most significant brick and mortar addition is the erecting of new 67.000 square foot facility in East Windsor, NJ. It will feature a state-of-the-art warehousing and distribution which will allow us to better serve the needs of our valued customer partners. The facility will also be the home for increased research and scientific study

Aurobindo Pharma USA is in the midst of a major expansion to its U.S. footprint. Read More »